Experimental eye drops restore vision in blind mice
Scientists develop potential treatment for photoreceptor degeneration-related blindness.
1The cause behind blindness
Photoreceptor degeneration underlies many causes of blindness, including age-related macular degeneration and retinitis pigmentosa. These disorders affect approximately 200 million people worldwide and rank among leading causes of vision loss. Beyond impacting independence and quality of life, visual impairment creates a global economic burden exceeding $400 billion annually through healthcare costs and lost productivity.
2Limitations of current treatments
Current treatments for photoreceptor loss remain limited. Gene therapy only works for a small patient subset with specific mutations. Electronic retinal prostheses are invasive, costly and require extensive training. While optogenetics and light-sensitive drugs are in clinical testing, restoring high-quality vision under normal lighting conditions remains challenging.
3Novel molecular approach
A research consortium led by the Institute for Bioengineering of Catalonia (IBEC) has developed a new class of photoswitchable small-molecule drugs designed to restore visual functions in animal models of blindness. These compounds are engineered to assume some functions normally performed by photoreceptors. Deliverable via eye injection or drops, these methods require no genetic modification or implanted devices.
4Photopharmacology-based solution
Researchers employed photopharmacology, an approach enabling reversible light-controlled drug activity. By incorporating a light-sensitive molecular switch into drug chemistry, they developed a family of compounds called prosthe6. These molecules target ON-bipolar neurons to restore visual functions, representing a significant advancement in treatment possibilities.
5Success in animal models
The treatment restored innate light-avoidance behavior in mouse models of age-related macular degeneration and retinitis pigmentosa. While healthy mice instinctively prefer darker environments, blind mice lose this ability. After prosthe6 administration, blind mice spontaneously resumed dark area preference, strongly indicating treatment efficacy through measurable behavioral changes.
6Effectiveness in daily conditions
Crucially, the treatment worked under illumination levels comparable to indoor or overcast outdoor lighting. This suggests the approach could restore functional light perception in everyday environments. Particularly promising results came from prosthe6-12 and prosthe6-15 compounds, which proved effective both via eye injection and topical drop administration.
7Biological mechanism
Prosthe6 compounds target the mGlu6 protein within surviving retinal circuitry. When light reaches the eye, the molecules undergo shape changes that trigger retinal signaling resembling normal visual processing. This mechanism effectively substitutes some functions of lost photoreceptors. ON bipolar cells, which normally relay photoreceptor information through visual circuits, play a key role in this therapeutic approach.
8Hope for the future
These findings open new treatment possibilities for photoreceptor degeneration-related blindness. Current results demonstrate these molecules can be safely administered and potentially significantly improve patients' quality of life. The research team continues working to achieve similar outcomes in humans. This advancement holds particular promise for large patient groups ineligible for genetic therapies, representing a major step toward accessible vision restoration.